Additionally, the 36-month beta value for CAPR is 4.04. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CAPR is 40.01M and currently, short sellers hold a 9.61% ratio of that float. The average trading volume of CAPR on December 03, 2024 was 3.25M shares.
CAPR) stock’s latest price update
The stock price of Capricor Therapeutics Inc (NASDAQ: CAPR) has plunged by -11.97 when compared to previous closing price of 19.64, but the company has seen a -8.13% decline in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-02 that SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at the following upcoming investor conferences.
CAPR’s Market Performance
CAPR’s stock has fallen by -8.13% in the past week, with a monthly drop of -11.11% and a quarterly rise of 297.47%. The volatility ratio for the week is 7.16% while the volatility levels for the last 30 days are 8.61% for Capricor Therapeutics Inc The simple moving average for the past 20 days is -7.02% for CAPR’s stock, with a 105.87% simple moving average for the past 200 days.
Analysts’ Opinion of CAPR
Many brokerage firms have already submitted their reports for CAPR stocks, with Piper Sandler repeating the rating for CAPR by listing it as a “Overweight.” The predicted price for CAPR in the upcoming period, according to Piper Sandler is $35 based on the research report published on October 21, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CAPR reach a price target of $14. The rating they have provided for CAPR stocks is “Outperform” according to the report published on May 17th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to CAPR, setting the target price at $8 in the report published on January 05th of the current year.
CAPR Trading at -5.36% from the 50-Day Moving Average
After a stumble in the market that brought CAPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.11% of loss for the given period.
Volatility was left at 8.61%, however, over the last 30 days, the volatility rate increased by 7.16%, as shares sank -5.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +195.78% upper at present.
During the last 5 trading sessions, CAPR fell by -6.17%, which changed the moving average for the period of 200-days by +389.15% in comparison to the 20-day moving average, which settled at $18.61. In addition, Capricor Therapeutics Inc saw 253.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAPR starting from Nippon Shinyaku Co Ltd, who purchase 2,798,507 shares at the price of $5.36 back on Sep 20 ’24. After this action, Nippon Shinyaku Co Ltd now owns 7,090,351 shares of Capricor Therapeutics Inc, valued at $14,999,998 using the latest closing price.
Stock Fundamentals for CAPR
Current profitability levels for the company are sitting at:
- -1.55 for the present operating margin
- 0.96 for the gross margin
The net margin for Capricor Therapeutics Inc stands at -541.51. The total capital return value is set at 0.0. Equity return is now at value -102.63, with -52.44 for asset returns.
Currently, EBITDA for the company is -23.01 million with net debt to EBITDA at 1.92. When we switch over and look at the enterprise to sales, we see a ratio of 30.44. The receivables turnover for the company is 56.7for trailing twelve months and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.19.
Conclusion
In conclusion, Capricor Therapeutics Inc (CAPR) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
